Drug Database
Back to search

Poland· PL-100017902

Depo-Provera

A medroxyprogesterone product containing medroxyprogesteronum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 8 of our 19 countries.

ATC L02AB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDepo-ProveraATCL02AB02REGISTER NO.PL-100017902PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about medroxyprogesteronumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 8 of 19 countries.

Countries holding a registration under ATC L02AB02 (medroxyprogesterone), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search medroxyprogesterone products by name

Medroxyprogesterone · ATC L02AB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of medroxyprogesterone costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Medroxyprogesterone · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$5.69
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Medroxyprogesteronum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
L02AB02
ATC class
Medroxyprogesterone
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990236510
  • gtin
    05909990236527

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

241 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check medroxyprogesterone against other medicinesHow interaction checks work

Medroxyprogesterone · interactions on record

241 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Belgium · Depo-Provera, Provera
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • Finland · Farlutal, Provera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Norway · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fc18152d-6de2-4589-8377-50bed187bf61
GET /v1/drugs/fc18152d-6de2-4589-8377-50bed187bf61?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Zawiesina do wstrzykiwań",
  "source": "urpl",
  "strength": "150 mg/ml",
  "packaging": "05909990236510 ¦ Rp ¦ 3011\n1 fiol. 3,3 ml\n05909990236527 ¦ Rp ¦ 14324\n1 fiol. 6,7 ml",
  "substance": null,
  "common_name": "Medroxyprogesteronum",
  "pl_product_id": "100017902",
  "pozwolenie_nr": "02365",
  "auth_procedure": "NAR",
  "authorisation_validity": "2023-10-11"
}
API referenceMCP serverPlans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console